Alaunos Therapeutics, Inc. financial data

Symbol
TCRT on Nasdaq
Industry
Pharmaceutical Preparations
Location
2617 Bissonnet St, Suite 225, Houston, TX
State of incorporation
DE
Fiscal year end
December 31
Former names
ZIOPHARM ONCOLOGY INC (to 1/4/2022), EASYWEB INC (to 9/19/2005)
Latest financial report
10-Q - Q3 2024 - Nov 14, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 457 % +88.4%
Debt-to-equity 28 % -49.4%
Return On Equity -268 % -90.2%
Return On Assets -209 % -131%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 1.6M shares -99.3%
Common Stock, Shares, Outstanding 1.6M shares -99.3%
Entity Public Float 94.8M USD -57.2%
Common Stock, Value, Issued 2K USD -99.2%
Weighted Average Number of Shares Outstanding, Basic 1.6M shares +0.06%
Weighted Average Number of Shares Outstanding, Diluted 1.6M shares +0.06%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 6K USD
Research and Development Expense 1.38M USD -93.4%
General and Administrative Expense 6.04M USD -52.5%
Operating Income (Loss) -12M USD +65.5%
Nonoperating Income (Expense) 226K USD -87.8%
Net Income (Loss) Attributable to Parent -11.8M USD +67.7%
Earnings Per Share, Basic 7.7 USD/shares +86.8%
Earnings Per Share, Diluted 7.7 USD/shares +86.8%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 1.68M USD -85.9%
Assets, Current 3.55M USD -72.4%
Property, Plant and Equipment, Net 0 USD -100%
Operating Lease, Right-of-Use Asset 0 USD -100%
Other Assets, Noncurrent 0 USD -100%
Assets 3.55M USD -81.7%
Accounts Payable, Current 458K USD -64.7%
Accrued Liabilities, Current 368K USD -88%
Liabilities, Current 826K USD -82.3%
Other Liabilities, Noncurrent 0 USD -100%
Liabilities 826K USD -85.1%
Retained Earnings (Accumulated Deficit) -920M USD -1.3%
Stockholders' Equity Attributable to Parent 2.72M USD -80.4%
Liabilities and Equity 3.55M USD -81.7%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -1.92M USD +79.6%
Net Cash Provided by (Used in) Financing Activities 0 USD
Net Cash Provided by (Used in) Investing Activities 0 USD
Common Stock, Shares Authorized 5M shares -99%
Common Stock, Shares, Issued 1.6M shares -99.3%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -1.92M USD +87.7%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 1.68M USD -85.9%
Interest Paid, Excluding Capitalized Interest, Operating Activities 0 USD -100%
Deferred Tax Assets, Valuation Allowance 211M USD -10.9%
Deferred Tax Assets, Gross 211M USD -11.1%
Operating Lease, Liability 2.75M USD -47.7%
Depreciation 2K USD -99.7%
Payments to Acquire Property, Plant, and Equipment 0 USD -100%
Lessee, Operating Lease, Liability, to be Paid 3.24M USD -49.9%
Property, Plant and Equipment, Gross 15K USD -99.9%
Operating Lease, Liability, Current 0 USD
Lessee, Operating Lease, Liability, to be Paid, Year Two 780K USD -31.1%
Lessee, Operating Lease, Liability, to be Paid, Year One 757K USD -31.3%
Operating Lease, Weighted Average Discount Rate, Percent 0 pure -96.9%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 496K USD -59.6%
Lessee, Operating Lease, Liability, to be Paid, Year Three 804K USD -31%
Deferred Tax Assets, Operating Loss Carryforwards 148M USD -13.5%
Lessee, Operating Lease, Liability, to be Paid, Year Four 712K USD -40.7%
Operating Lease, Payments 100K USD
Deferred Tax Assets, Net of Valuation Allowance 0 USD -100%
Interest Expense 0 USD -100%